Rates of nausea were notably higher than with tirzepatide alone, which is consistent with the additive effect on gastric motility
General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data
Service getting the meds has been great
Outcome Most people notice falling asleep gets easier within the first few nights, with mornings feeling less groggy by weeks 12 and genuinely restorative sleep by weeks 24
Researchers examining DSIP peptide in Australia often focus on its involvement in sleep-related signalling and recovery-associated pathways in controlled research environments
This relates to a lack of RBCs and a fast heartbeat